Researchers at the Montreal Clinical Research Institute (IRCM) have made a groundbreaking discovery that could revolutionize the treatment of inflammatory bowel disease (IBD). Their study, recently published in the prestigious journal Blood, revealed the potential of a naturally occurring molecule called Beta-hydroxybutyrate (BHB) in combating inflammation in the intestines.
Led by Emilia Liana Falcone, the director of IRCM’s microbiome and defense research unit, the study originally focused on a rare inherited disease known as chronic granulomatous disease (CGD), which often leads to inflammatory bowel diseases. The team found that a ketogenic diet, which promotes the production of BHB in the body, effectively reduced intestinal inflammation in mice with CGD.
Inflammatory bowel disease, a chronic condition affecting the digestive system, can cause a range of debilitating symptoms such as abdominal pain, fatigue, and arthritis. Despite affecting over 322,000 Canadians, the exact cause of IBD remains unknown.
The discovery of BHB’s anti-inflammatory properties has sparked hope for potential new treatments for IBD, beyond just CGD. Falcone and her team are now exploring the possibility of utilizing BHB in future clinical trials, aiming to develop targeted therapies that do not require a ketogenic diet.
Excited by the promising results, Falcone has engaged in discussions with the National Institutes of Health in the U.S., exploring the potential application of BHB in treating IBD on a larger scale. The implications of this research could offer new hope for the millions of individuals suffering from inflammatory bowel diseases worldwide.
Keyphrase: IBD treatment discovery
